What is the current valuation of the UK RNA based-therapeutics market?

The market valuation was $659.38 Million in 2024. Read More

What is the projected market size for the UK RNA based-therapeutics market by 2035?

The projected valuation for 2035 is $1265.0 Million. Read More

What is the expected CAGR for the UK RNA based-therapeutics market during the forecast period 2025 - 2035?

The expected CAGR is 6.1% during the forecast period. Read More

What were the valuations for mRNA Therapeutics in 2024?

The valuation for mRNA Therapeutics ranged from $250.0 Million to $500.0 Million. Read More

Which applications are most prominent in the UK RNA based-therapeutics market?

Prominent applications include Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases. Read More

What was the valuation range for Oncology applications in 2024?

The valuation for Oncology applications ranged from $200.0 Million to $400.0 Million. Read More

Who are the key players in the UK RNA based-therapeutics market?

Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, CureVac, Sangamo Therapeutics, Arcturus Therapeutics, and Translate Bio. Read More

What delivery methods are utilized in the UK RNA based-therapeutics market?

Delivery methods include Liposomes, Nanoparticles, Viral Vectors, and Electroporation. Read More

What was the valuation for Viral Vectors in 2024?

The valuation for Viral Vectors ranged from $200.0 Million to $400.0 Million. Read More

UK RNA-based Therapeutics Market

Q: Which technology segments are driving the UK RNA based-therapeutics market?

Key technology segments include RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology. Read More

ID: MRFR/HC/50891-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

UK RNA-Based Therapeutics Market Research Report By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Application (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) and By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) - Growth & Industry Forecast 2025 To 2035

UK RNA-based Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Technology (USD Million)
  1. 4.1.1 RNA Interference
  2. 4.1.2 Antisense Oligonucleotides
  3. 4.1.3 mRNA Therapeutics
  4. 4.1.4 CRISPR Technology
2. 4.2 Industrial Automation & Equipment, BY Application (USD Million)
  1. 4.2.1 Oncology
  2. 4.2.2 Infectious Diseases
  3. 4.2.3 Genetic Disorders
  4. 4.2.4 Cardiovascular Diseases
3. 4.3 Industrial Automation & Equipment, BY End Use (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Research Institutions
  3. 4.3.3 Contract Research Organizations
4. 4.4 Industrial Automation & Equipment, BY Delivery Method (USD Million)
  1. 4.4.1 Liposomes
  2. 4.4.2 Nanoparticles
  3. 4.4.3 Viral Vectors
  4. 4.4.4 Electroporation
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Moderna (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 BioNTech (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Alnylam Pharmaceuticals (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Ionis Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 CureVac (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sangamo Therapeutics (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Arcturus Therapeutics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Translate Bio (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY TECHNOLOGY
3. 6.3 UK MARKET ANALYSIS BY APPLICATION
4. 6.4 UK MARKET ANALYSIS BY END USE
5. 6.5 UK MARKET ANALYSIS BY DELIVERY METHOD
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TECHNOLOGY, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USE, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USE, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DELIVERY METHOD, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY END USE, 2025-2035 (USD Million)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Technology (USD Million, 2025-2035)

RNA Interference
Antisense Oligonucleotides
mRNA Therapeutics
CRISPR Technology

Industrial Automation & Equipment By Application (USD Million, 2025-2035)

Oncology
Infectious Diseases
Genetic Disorders
Cardiovascular Diseases

Industrial Automation & Equipment By End Use (USD Million, 2025-2035)

Pharmaceutical Companies
Research Institutions
Contract Research Organizations

Industrial Automation & Equipment By Delivery Method (USD Million, 2025-2035)

Liposomes
Nanoparticles
Viral Vectors
Electroporation

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”